Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry

Development of first-generation thrombopoietins (TPOs) was halted due to antibodies that neutralized endogenous TPO, causing protracted thrombocytopenia in some patients. The second-generation TPO receptor agonist romiplostim, having no homology to TPO, was developed to circumvent potential immunoge...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowers, Charles, Mytych, Daniel T., Lawrence, Tatiana, Wang, Kejia, Barger, Troy E., Eisen, Melissa, Bennett, Carolyn M., Tarantino, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Platelets and Thrombopoiesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153015/
https://www.ncbi.nlm.nih.gov/pubmed/34638135
http://dx.doi.org/10.1182/bloodadvances.2021005105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153015/
https://www.ncbi.nlm.nih.gov/pubmed/34638135
http://dx.doi.org/10.1182/bloodadvances.2021005105

Ejemplares similares